Roivant Sciences Ltd. (ROIV) Tops Q2 EPS by 15c

Roivant Sciences Ltd. (NASDAQ: ROIV) reported Q2 EPS of ($0.17), $0.15 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $1.57 million versus the consensus estimate of $5.6 million.

For earnings history and earnings-related data on Roivant Sciences Ltd. (ROIV) click here.

You May Also Be Interested In

• Roivant Sciences (ROIV) Reiterated at Overweight by Cantor Fitzgerald: 'Thesis Unchanged'
• Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
• Lululemon (LULU) PT Lowered to $120 at UBS on Expectations for Lowered FY26 Guidance